{"transactions":[{"id":743102,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:08:29.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001545794-26-000001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000154579426000001/ownership.xml","form_type":"4"}},{"id":743101,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:08:29.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":35148,"source":{"system":"sec-edgar","filing":"0001545794-26-000001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000154579426000001/ownership.xml","form_type":"4"}},{"id":1111611,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:36:09.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086287/ownership.xml","form_type":"4"}},{"id":1111610,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:36:09.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":25948,"source":{"system":"sec-edgar","filing":"0000950170-25-086287","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086287/ownership.xml","form_type":"4"}},{"id":1473183,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:00:43.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":1505,"price":25,"value":37625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 1,505 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 7, 2024."}],"balance_after":17948,"source":{"system":"sec-edgar","filing":"0000950170-24-075718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024075718/ownership.xml","form_type":"4"}},{"id":1478964,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:22:25.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":11515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11515,"derivative":{"exercise_price":25.85,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":11515},"source":{"system":"sec-edgar","filing":"0000950170-24-073704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024073704/ownership.xml","form_type":"4"}},{"id":1478963,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T20:22:25.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":7737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":19453,"source":{"system":"sec-edgar","filing":"0000950170-24-073704","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024073704/ownership.xml","form_type":"4"}},{"id":1852198,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:29:38.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":6473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":6473,"derivative":{"exercise_price":45.2,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":6473},"source":{"system":"sec-edgar","filing":"0001209191-23-037898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123037898/doc4.xml","form_type":"4"}},{"id":1852197,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:29:38.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":4425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":11716,"source":{"system":"sec-edgar","filing":"0001209191-23-037898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123037898/doc4.xml","form_type":"4"}},{"id":2229947,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T22:46:11.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":7688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":7688,"derivative":{"exercise_price":38.49,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":7688},"source":{"system":"sec-edgar","filing":"0001209191-22-037604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122037604/doc4.xml","form_type":"4"}},{"id":2229946,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T22:46:11.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":5197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":7291,"source":{"system":"sec-edgar","filing":"0001209191-22-037604","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122037604/doc4.xml","form_type":"4"}},{"id":2654780,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-25T22:14:42.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":3382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":3382,"derivative":{"exercise_price":83.59,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":3382},"source":{"system":"sec-edgar","filing":"0001209191-21-043385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121043385/doc4.xml","form_type":"4"}},{"id":2654779,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T22:14:42.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":2094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":2094,"source":{"system":"sec-edgar","filing":"0001209191-21-043385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121043385/doc4.xml","form_type":"4"}},{"id":3104328,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T20:47:23.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":20.72,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-037971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120037971/doc4.xml","form_type":"4"}},{"id":3299399,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:48.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001562180-20-000678","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000678/primarydocument.xml","form_type":"4"}},{"id":3299398,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:48.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000678","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000678/primarydocument.xml","form_type":"4"}},{"id":3299397,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:48.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000678","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000678/primarydocument.xml","form_type":"4"}},{"id":3299396,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:16:48.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000678","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000678/primarydocument.xml","form_type":"4"}},{"id":3515323,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-22T20:36:11.000Z","date":"2019-05-21","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 21, 2019 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":15.78,"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-19-032086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919119032086/doc4.xml","form_type":"4"}},{"id":3686970,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-25T16:55:48.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in equal quarterly installments over the one-year period following the date of grant."}],"balance_after":42000,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-19-005384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919119005384/doc4.xml","form_type":"4"}},{"id":3924064,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-21T16:51:16.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 17, 2018 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":25.98,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-18-031688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919118031688/doc4.xml","form_type":"4"}},{"id":3933015,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:42:38.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":2905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":2905},"source":{"system":"sec-edgar","filing":"0001209191-18-030132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030132/doc4.xml","form_type":"4"}},{"id":3933014,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:42:38.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":69.25,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2454},"source":{"system":"sec-edgar","filing":"0001209191-18-030132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030132/doc4.xml","form_type":"4"}},{"id":3933013,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:42:38.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":26496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2026-02-10","underlying":"Common Stock","underlying_shares":26496},"source":{"system":"sec-edgar","filing":"0001209191-18-030132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030132/doc4.xml","form_type":"4"}},{"id":3933012,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-15T12:42:38.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":1106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 1,106 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-030132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030132/doc4.xml","form_type":"4"}},{"id":3978774,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-30T17:51:04.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":2905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."}],"balance_after":2905,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":2905},"source":{"system":"sec-edgar","filing":"0001209191-18-022240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118022240/doc4.xml","form_type":"4"}},{"id":3978773,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-30T17:51:04.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":1106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."}],"balance_after":1106,"source":{"system":"sec-edgar","filing":"0001209191-18-022240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118022240/doc4.xml","form_type":"4"}},{"id":4063623,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2018-02-13T17:13:19.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter."}],"balance_after":30000,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-009651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118009651/doc4.xml","form_type":"4"}},{"id":4251890,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-25T20:49:08.000Z","date":"2017-07-25","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter."}],"balance_after":38000,"derivative":{"exercise_price":16.91,"expiration_date":"2027-07-24","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001209191-17-046194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117046194/doc4.xml","form_type":"4"}},{"id":4298186,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-01T18:08:05.000Z","date":"2017-05-30","kind":"grant","acquired":true,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable (i) in twelve equal monthly installments beginning on June 30, 2017, or (ii) on the date of the Issuer's next annual stockholder meeting, whichever comes first, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Issuer's 2016 Equity Incentive Plan) through each such date."}],"balance_after":2454,"derivative":{"exercise_price":69.25,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2454},"source":{"system":"sec-edgar","filing":"0001209191-17-036899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117036899/doc4.xml","form_type":"4"}},{"id":4486927,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2017-01-19T17:28:58.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter."}],"balance_after":30000,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-004622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919117004622/doc4.xml","form_type":"4"}}]}